Q-omics provides the consensus-scored MFSD13A profile across patient tissues and cancer cell-line models. MFSD13A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MFSD13A is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, MFSD13A RNA expression shows 18,451 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where MFSD13A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MFSD13A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MFSD13A survival associations across molecular data types. MFSD13A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MFSD13A RNA expression–survival associations across cancer types. High MFSD13A expression shows unfavorable associations in ACC, THCA and LIHC, but favorable associations in SCLC, LGG and STAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MFSD13A RNA expression.
This table summarizes MFSD13A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MFSD13A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MFSD13A shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, BLCA, STAD and LIHC. The HNSC box plot shows higher MFSD13A RNA expression in tumor versus normal tissue (log2 FC = +1.103, t-test p < 0.001).
This table shows molecular features associated with MFSD13A in patient tissues and cancer cell lines. In patient samples, MFSD13A shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MFSD13A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SOFT_TISSUE.
